| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 151 | 2021 |
| Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases IM Subbiah, X Lei, JS Weinberg, EP Sulman, M Chavez-MacGregor, ... Journal of Clinical Oncology 33 (20), 2239, 2015 | 128 | 2015 |
| Hyperprogression and immunotherapy: fact, fiction, or alternative fact? JJ Adashek, IM Subbiah, I Matos, E Garralda, AK Menta, DM Ganeshan, ... Trends in cancer 6 (3), 181-191, 2020 | 101 | 2020 |
| Cardiovascular toxicity profiles of vascular‐disrupting agents IM Subbiah, DJ Lenihan, AM Tsimberidou The oncologist 16 (8), 1120-1130, 2011 | 100 | 2011 |
| NCCN guidelines® insights: older adult oncology, version 1.2021: featured updates to the NCCN guidelines E Dotan, LC Walter, IS Browner, K Clifton, HJ Cohen, M Extermann, ... Journal of the National Comprehensive Cancer Network 19 (9), 1006-1019, 2021 | 98 | 2021 |
| STUMP un “stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features … V Subbiah, C McMahon, S Patel, R Zinner, EG Silva, JA Elvin, IM Subbiah, ... Journal of Hematology & Oncology 8, 1-7, 2015 | 85 | 2015 |
| Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma AO Kaseb, M Shama, IH Sahin, A Nooka, HM Hassabo, JN Vauthey, ... Oncology 85 (4), 197-203, 2013 | 83 | 2013 |
| Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update W Dale, HD Klepin, GR Williams, SMH Alibhai, C Bergerot, ... Journal of Clinical Oncology 41 (26), 4293-4312, 2023 | 79 | 2023 |
| Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study … SJ Mayo, M Lustberg, H M Dhillon, ZM Nakamura, DH Allen, D Von Ah, ... Supportive Care in Cancer 29, 2821-2840, 2021 | 77 | 2021 |
| Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases V Subbiah, J Berry, M Roxas, N Guha-Thakurta, IM Subbiah, SM Ali, ... Lung Cancer 89 (1), 76-79, 2015 | 73 | 2015 |
| Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview A Chan, DL Hertz, M Morales, EJ Adams, S Gordon, CJ Tan, NP Staff, ... Supportive care in cancer 27, 3729-3737, 2019 | 69 | 2019 |
| Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers JJ Adashek, IM Subbiah ESMO open 5 (5), e000862, 2020 | 60 | 2020 |
| Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma AM Heilmann, V Subbiah, K Wang, JX Sun, JA Elvin, J Chmielecki, ... Oncology 90 (6), 339-346, 2016 | 54 | 2016 |
| Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials D Pasalic, GJ McGinnis, CD Fuller, AJ Grossberg, V Verma, ... European Journal of Cancer 136, 176-185, 2020 | 39 | 2020 |
| Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials IM Subbiah, V Subbiah, AM Tsimberidou, A Naing, AO Kaseb, M Javle, ... Oncotarget 4 (1), 153, 2013 | 38 | 2013 |
| Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials S Sen, K Hess, DS Hong, A Naing, S Piha-Paul, F Janku, S Fu, ... British journal of cancer 118 (6), 763-769, 2018 | 37 | 2018 |
| Current update on gallbladder carcinoma D Ganeshan, A Kambadakone, P Nikolaidis, V Subbiah, IM Subbiah, ... Abdominal Radiology 46, 2474-2489, 2021 | 35 | 2021 |
| Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape IM Subbiah, A Tsimberidou, V Subbiah, F Janku, S Roy-Chowdhuri, ... Oncoscience 4 (5-6), 47, 2017 | 32 | 2017 |
| Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies XS Wang, SA Srour, M Whisenant, IM Subbiah, TH Chen, D Ponce, ... Transplantation and Cellular Therapy 27 (11), 930. e1-930. e10, 2021 | 31 | 2021 |
| Financial burden of drugs prescribed for cancer-associated symptoms A Gupta, L Nshuti, US Grewal, R Sedhom, DK Check, HM Parsons, ... JCO Oncology Practice 18 (2), 140-147, 2022 | 29 | 2022 |
